enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - porcos - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.
suiseng diff/a suspensão injetável para suínos
clostridioides difficile, toxoid b (tcdb) 1.65 ; clostridium perfringens tipo a, α-toxoide 1.34 ; clostridioides difficile, toxoide a (tcda) 1.6 - suínos
nexviadyme
sanofi b.v. - avalglucosidase alfa - doença de armazenamento de glicogênio tipo ii - outro aparelho digestivo e metabolismo produtos, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).
tansulosina aurovitas 0.4 mg cápsula de libertação prolongada
generis farmacêutica, s.a. - tansulosina - cápsula de libertação prolongada - 0.4 mg - tansulosina, cloridrato 0.4 mg - tamsulosin - genérico - duração do tratamento: longa duração
tansulosina aurovitas 0.4 mg cápsula de libertação prolongada
generis farmacêutica, s.a. - tansulosina - cápsula de libertação prolongada - 0.4 mg - tansulosina, cloridrato 0.4 mg - tamsulosin - genérico - duração do tratamento: longa duração
tansulosina generis 0.4 mg comprimido de libertação prolongada
generis farmacêutica, s.a. - tansulosina - comprimido de libertação prolongada - 0.4 mg - tansulosina, cloridrato 0.4 mg - tamsulosin - genérico - duração do tratamento: longa duração
pombiliti
amicus therapeutics europe limited - cipaglucosidase alfa - doença de armazenamento de glicogênio tipo ii - outro aparelho digestivo e metabolismo produtos, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).
elfabrio
chiesi farmaceutici s.p.a - pegunigalsidase alfa - doença de fabry - outro aparelho digestivo e metabolismo produtos, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).
opfolda
amicus therapeutics europe limited - miglustat - doença de armazenamento de glicogênio tipo ii - outros produtos do trato digestivo e do metabolismo - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).
zeel-artro
heel do brasil biomÉdica ltda - cartilago suis, funiculus umbilicalis suis, embryo suis , placenta suis, dulcamara, symphytum officinale, nadidum, coenzyme a, sanguinaria canadensis, dietiloxalacetato de sÓdio, acidum alpha-lipoicum, rhus toxicodendron, arnica montana, sulphur - antinflamatorios antireumaticos